This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
CRI’s Jill O'Donnell-Tormey chats with STAT about the lifesaving potential of bispecific antibodies.
CRI’s Samik Upadhaya, Ph.D., discusses the current cell therapy landscape in immuno-oncology.
CRI’s Jill O'Donnell-Tormey chats with the Focused Ultrasound Foundation about the lifesaving potential of cancer immunotherapy.
CRI’s Jill O'Donnell-Tormey is a panelist on the virtual roundtable discussing predictions for ASCO21.
CRI’s Samik Upadhaya, Ph.D., speaks on the "Mitigating the impact of covid-19 and future public health emergencies on oncology clinical trials" panel on May 5.
CRI’s Jay Campbell speaks on the “Investing in the Emerald City of Oncology Innovation" panel on May 6.
CRI’s Jay Campbell speaks on the “Innovating Finance, Non-Traditional Funding Sources" panel on April 29.
CRI's Samik Upadhaya, Ph.D., speaks on the "Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies" panel on February 25.
CRI's Annie Yu, Ph.D., speaks on the “How COVID-19 Changed Clinical Trial Dynamics and Environment” panel on January 27.
CRI's Jill O'Donnell-Tormey, Ph.D., moderates the cancer immunotherapy panel on November 10, 2020, at 10:35 AM ET.
CRI's Jill O'Donnell-Tormey, Ph.D., speaks on the "Public-Private Partnerships Between Research Organizations and BioPharma to Accelerate Cancer Immunotherapies" panel on October 2, 2020, at 1 PM ET.
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Help us cheer on our Team CRI members who have been not only training for a marathon, but also helping to raise funds for a future immune to cancer.
This October for Liver Cancer Awareness Month, let’s delve into new treatments, research insights, and how we are fueling a future immune to liver cancer.